Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alirinetide - Genervon

Next Previous
Drug Profile

Alirinetide - Genervon

Alternative Names: GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genervon Biopharmaceuticals
  • Class Antidementias; Antiparkinsonians; Neuroprotectants; Peptides; Vascular disorder therapies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; Apoptosis inhibitors; Bcl-X protein inhibitors; Free radical inhibitors; Insulin receptor modulators; Nervous system modulators; Neurogenesis modulators; Proto-oncogene protein c-akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Ischaemic stroke; Parkinson's disease
  • No development reported Alzheimer's disease; Huntington's disease; Multiple sclerosis; Musculoskeletal disorders; Spinal cord injuries

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in USA (IV)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in USA (IV)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Spinal-cord-injuries(In volunteers) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top